Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17Stephanie Yasmin Brule, Rachel Goodwin, Malcolm J. Moore et al.|European Journal of Cancer|2015Cited by 337
Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trialMichele Maio, Bohuslav Melichar, Karl D. Lewis et al.|The Lancet Oncology|2018Cited by 216